Cargando…
Efficacy and Safety of Systemic and Locoregional Cisplatin Chronotherapy in Rats with Ovarian Carcinoma
AIM: Alterations in circadian rhythms caused by tumor growth are thought to be clinically relevant as they affect the prognosis and treatment response. We aimed to evaluate the chronotherapeutic approach in rats with ovarian cancer receiving cisplatin intravenously (IV) or with hyperthermic intraper...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8163628/ https://www.ncbi.nlm.nih.gov/pubmed/34079283 http://dx.doi.org/10.2147/OTT.S309285 |
_version_ | 1783700945188683776 |
---|---|
author | Kireeva, Galina Gubareva, Ekaterina Maydin, Mikhail Osetnik, Vladislav Kruglov, Stepan Panchenko, Andrey Dorofeeva, Anastasia Tyndyk, Margarita Fedoros, Elena Anisimov, Vladimir |
author_facet | Kireeva, Galina Gubareva, Ekaterina Maydin, Mikhail Osetnik, Vladislav Kruglov, Stepan Panchenko, Andrey Dorofeeva, Anastasia Tyndyk, Margarita Fedoros, Elena Anisimov, Vladimir |
author_sort | Kireeva, Galina |
collection | PubMed |
description | AIM: Alterations in circadian rhythms caused by tumor growth are thought to be clinically relevant as they affect the prognosis and treatment response. We aimed to evaluate the chronotherapeutic approach in rats with ovarian cancer receiving cisplatin intravenously (IV) or with hyperthermic intraperitoneal chemoperfusion (HIPEC) and to assess daily variations in tumor and intestinal epithelium proliferation. METHODS: In the pilot study, we used 12 intact rats and 12 rats with transplantable ovarian cancer, which were euthanized at ZT0 (08:00, lights on), ZT6, ZT12 and ZT18. In the main study, we used 45 rats with transplantable ovarian cancer. Animals were randomized into five groups: control, HIPEC with cisplatin at ZT0 (08:00), HIPEC with cisplatin at ZT12 (20:00), IV cisplatin at ZT0 and IV cisplatin at ZT12. We assessed the proliferation rate of tumor and small intestinal epithelium, apoptosis in small intestinal epithelium, and levels of γ-H2AX (DNA damage/repair marker) in kidneys and liver. Survival was calculated in each group. RESULTS: Ascitic ovarian cancer disrupted daily variations in intestinal epithelium proliferation and DNA damage/repair in rats. Ovarian carcinoma exhibited no daily variation in mitotic activity. In animals receiving IV cisplatin, massive cell damage in the renal medulla and cystic changes within renal tubules were observed, unlike in rats receiving HIPEC. Tumor mitotic activity was lower in morning-treated groups. The median survival of rats in the control group was 8.5 days (95% CI 6.0–22.0), in HIPEC at ZT0 40.5 days (95% CI 28.0–47.0, p<0.001) and in HIPEC at ZT12 32.0 days (95% CI 28.0–37.0, p<0.001). CONCLUSION: In a rat model, ovarian tumor growth disrupted daily variations in intestinal epithelium proliferation and caused genotoxic stress in tumor-free tissues. HIPEC with cisplatin at ZT0 had a better efficacy/toxicity profile than HIPEC with cisplatin at ZT12 and IV administration at both time points. |
format | Online Article Text |
id | pubmed-8163628 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-81636282021-06-01 Efficacy and Safety of Systemic and Locoregional Cisplatin Chronotherapy in Rats with Ovarian Carcinoma Kireeva, Galina Gubareva, Ekaterina Maydin, Mikhail Osetnik, Vladislav Kruglov, Stepan Panchenko, Andrey Dorofeeva, Anastasia Tyndyk, Margarita Fedoros, Elena Anisimov, Vladimir Onco Targets Ther Original Research AIM: Alterations in circadian rhythms caused by tumor growth are thought to be clinically relevant as they affect the prognosis and treatment response. We aimed to evaluate the chronotherapeutic approach in rats with ovarian cancer receiving cisplatin intravenously (IV) or with hyperthermic intraperitoneal chemoperfusion (HIPEC) and to assess daily variations in tumor and intestinal epithelium proliferation. METHODS: In the pilot study, we used 12 intact rats and 12 rats with transplantable ovarian cancer, which were euthanized at ZT0 (08:00, lights on), ZT6, ZT12 and ZT18. In the main study, we used 45 rats with transplantable ovarian cancer. Animals were randomized into five groups: control, HIPEC with cisplatin at ZT0 (08:00), HIPEC with cisplatin at ZT12 (20:00), IV cisplatin at ZT0 and IV cisplatin at ZT12. We assessed the proliferation rate of tumor and small intestinal epithelium, apoptosis in small intestinal epithelium, and levels of γ-H2AX (DNA damage/repair marker) in kidneys and liver. Survival was calculated in each group. RESULTS: Ascitic ovarian cancer disrupted daily variations in intestinal epithelium proliferation and DNA damage/repair in rats. Ovarian carcinoma exhibited no daily variation in mitotic activity. In animals receiving IV cisplatin, massive cell damage in the renal medulla and cystic changes within renal tubules were observed, unlike in rats receiving HIPEC. Tumor mitotic activity was lower in morning-treated groups. The median survival of rats in the control group was 8.5 days (95% CI 6.0–22.0), in HIPEC at ZT0 40.5 days (95% CI 28.0–47.0, p<0.001) and in HIPEC at ZT12 32.0 days (95% CI 28.0–37.0, p<0.001). CONCLUSION: In a rat model, ovarian tumor growth disrupted daily variations in intestinal epithelium proliferation and caused genotoxic stress in tumor-free tissues. HIPEC with cisplatin at ZT0 had a better efficacy/toxicity profile than HIPEC with cisplatin at ZT12 and IV administration at both time points. Dove 2021-05-24 /pmc/articles/PMC8163628/ /pubmed/34079283 http://dx.doi.org/10.2147/OTT.S309285 Text en © 2021 Kireeva et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Kireeva, Galina Gubareva, Ekaterina Maydin, Mikhail Osetnik, Vladislav Kruglov, Stepan Panchenko, Andrey Dorofeeva, Anastasia Tyndyk, Margarita Fedoros, Elena Anisimov, Vladimir Efficacy and Safety of Systemic and Locoregional Cisplatin Chronotherapy in Rats with Ovarian Carcinoma |
title | Efficacy and Safety of Systemic and Locoregional Cisplatin Chronotherapy in Rats with Ovarian Carcinoma |
title_full | Efficacy and Safety of Systemic and Locoregional Cisplatin Chronotherapy in Rats with Ovarian Carcinoma |
title_fullStr | Efficacy and Safety of Systemic and Locoregional Cisplatin Chronotherapy in Rats with Ovarian Carcinoma |
title_full_unstemmed | Efficacy and Safety of Systemic and Locoregional Cisplatin Chronotherapy in Rats with Ovarian Carcinoma |
title_short | Efficacy and Safety of Systemic and Locoregional Cisplatin Chronotherapy in Rats with Ovarian Carcinoma |
title_sort | efficacy and safety of systemic and locoregional cisplatin chronotherapy in rats with ovarian carcinoma |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8163628/ https://www.ncbi.nlm.nih.gov/pubmed/34079283 http://dx.doi.org/10.2147/OTT.S309285 |
work_keys_str_mv | AT kireevagalina efficacyandsafetyofsystemicandlocoregionalcisplatinchronotherapyinratswithovariancarcinoma AT gubarevaekaterina efficacyandsafetyofsystemicandlocoregionalcisplatinchronotherapyinratswithovariancarcinoma AT maydinmikhail efficacyandsafetyofsystemicandlocoregionalcisplatinchronotherapyinratswithovariancarcinoma AT osetnikvladislav efficacyandsafetyofsystemicandlocoregionalcisplatinchronotherapyinratswithovariancarcinoma AT kruglovstepan efficacyandsafetyofsystemicandlocoregionalcisplatinchronotherapyinratswithovariancarcinoma AT panchenkoandrey efficacyandsafetyofsystemicandlocoregionalcisplatinchronotherapyinratswithovariancarcinoma AT dorofeevaanastasia efficacyandsafetyofsystemicandlocoregionalcisplatinchronotherapyinratswithovariancarcinoma AT tyndykmargarita efficacyandsafetyofsystemicandlocoregionalcisplatinchronotherapyinratswithovariancarcinoma AT fedoroselena efficacyandsafetyofsystemicandlocoregionalcisplatinchronotherapyinratswithovariancarcinoma AT anisimovvladimir efficacyandsafetyofsystemicandlocoregionalcisplatinchronotherapyinratswithovariancarcinoma |